BEJCKOVA, Alzbeta, Miloslav MAREL, Zdenka CHLADKOVA, Libor FILA, Luis Fernando CASAS-MENDEZ, Ondřej VENCLÍČEK, Petr JAKUBEC, Marketa CERNOVSKA, Michal HRNCIARIK, Jana KREJCI, Petr DOMECKY and Martin SVATON. Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project. Biomedical Papers. Olomouc: Palacky University, 2024, 8 pp. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2024.019.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project
Authors BEJCKOVA, Alzbeta, Miloslav MAREL, Zdenka CHLADKOVA, Libor FILA, Luis Fernando CASAS-MENDEZ, Ondřej VENCLÍČEK, Petr JAKUBEC, Marketa CERNOVSKA, Michal HRNCIARIK, Jana KREJCI, Petr DOMECKY and Martin SVATON.
Edition Biomedical Papers, Olomouc, Palacky University, 2024, 1213-8118.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.900 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.5507/bp.2024.019
UT WoS 001261202100001
Keywords in English small cell lung cancer; extensive-stage; carboplatin; cisplatin
Tags 14110215
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 12/7/2024 10:36.
Abstract
Background. Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a poor prognosis. The standard palliative treatment for four decades has been chemotherapy as a combination of etoposide with carboplatin or cisplatin, and in recent years, immunotherapy in addition. Aims. To determine whether there is a difference in the efficacy of palliative chemotherapy as cisplatin or carboplatin in combination with etoposide in patients with ES-SCLC in real-world practice in the Czech Republic. Methods. This was a retrospective analysis of a cohort of 348 patients from the LUCAS project with ES-SCLC. 79 were treated with etoposide plus cisplatin and 265 were treated with etoposide plus carboplatin. Kaplan-Meier curves and the Cox regression model were used for analysis. Results. No statistically significant difference in median overall survival (mOS) or median progression free survival (mPFS) was found between groups or between patients grouped according to age and performance status (PS) in mOS. The Cox regression result was similar. Conclusion. This study shows that cisplatin and carboplatin do not differ in efficacy in a given indication, thus when choosing a treatment, the physician should consider the expected toxicity in a particular patient, assessing the patient's general condition and comorbidities.
PrintDisplayed: 10/8/2024 05:27